Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial …

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.According to Adam Mendelsohn, Chief Executive Officer, “2022 was truly a transformational year for the Company, including the business combination of Nano Precision Medical (“NPM”) and Second Sight Medical Products (“Second Sight”), into our newly merged company, Vivani Medical, Inc. We made significant progress with our lead program, NPM-119, a miniature, 6-month, GLP-1 implant candidate for the treatment of patients with type 2 diabetes using our proprietary NanoPortal(TM) implant technology. We continue to believe that NPM-119 has the potential to significantly improve real-world outcomes for the approximately half of patients with type 2 diabetes who are non-adherent with their medication.

We also believe that NPM-119 has the potential to demonstrate an improved gastrointestinal side-effect profile compared to other available GLP-1 treatment options because of NPM-119’s steady drug delivery profile. After successful completion of the non-clinical toxicology and other supportive studies, we plan to submit an Investigational New Drug (“IND”) application and initiate our proposed first-in-human, randomized, Phase 2 clinical trial, named LIBERATE-1, in mid-2023. After years of development, it is very exciting to be approaching the first clinical application of our proprietary NanoPortal implant platform technology.”Dr.

Mendelsohn further added, “I am also very proud of the significant progress achieved by our Neuromodulation Division, now known as Cortigent Inc., in collaboration with our new leadership team in identifying strategic options to support the further development of the division’s pioneering neurostimulation systems aimed at helping patients recover critical body functions.”Recent Business HighlightsIn July 2022, Vivani generated encouraging 6-month, preclinical, proof-of-concept data using a prototype implant configuration that we plan to develop and evaluate further in the clinical setting.In August 2022, the business combination of Second Sight and NPM was completed, and the combined company was renamed Vivani. Since the business combination, Vivani’s main priority has been the further development of the Company’s lead program, NPM-119, a miniature, 6-month, GLP-1 implant candidate for the treatment of patients with type 2 diabetes under the Company’s Biopharm Division (formerly NPM). In parallel, Vivani’s new management team remains committed to identifying and exploring strategic options for the Neuromodulation Division (formerly Second Sight) that will enable further development of its pioneering neurostimulation systems.In November 2022, Vivani’s neuromodulation business was established as a wholly-owned subsidiary named Cortigent, Inc., a Delaware corporation.In January 2023, Vivani successfully completed the IND-enabling, non-clinical toxicology and biocompatibility studies to support the planned IND submission for NPM-119 (exenatide implant) under development for the treatment of patients with type 2 diabetes.

By mid-2023, we plan to file the IND with the U.S. Food and Drug Administration (the “FDA”) and, if clearance is obtained, initiate our first-in-human, randomized, 12-week, Phase 2 clinical trial of NPM-119 (exenatide implant) in patients with type 2 diabetes, which we have designated as LIBERATE-1. The primary objective will be investigation of the safety, tolerability, and full pharmacokinetic profile of NPM-119.

Bydureon Bcise(R) (exenatide extended-release injectable suspension) will also be included in the trial as an active comparator. Secondary objectives will include glycemic lowering and the study will also be evaluating changes in weight.In March 2023, Vivani announced the filing of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) for the proposed initial public offering of Cortigent, Inc. (“Cortigent”).

Cortigent was formed for the purpose of advancing Vivani’s neuromodulation division and is expected to continue to be controlled by Vivani following the initial public offering.Moving forward, Vivani’s focus will be on its Biopharm Division and the further development of NPM-119 and its emerging pipeline of innovative miniature, long-term drug implant candidates to treat patients with chronic diseases and high unmet medical need. Today, the Company’s Biopharm Division has grown to nearly 40 full-time employees and its current headquarters and operations are located at 5858 Horton Street, Emeryville, California.Upcoming Anticipated MilestonesWe anticipate the filing of the NPM-119 (exenatide implant) IND with the FDA and, subject to IND clearance, we anticipate initiating LIBERATE-1 in mid-2023, and expect to report top-line results in the first half of 2024.2022 Financial ResultsCash Balance: As of December 31, 2022, Vivani had cash and cash equivalents totaling £45.1 million compared to £2.2 million in year ended December 31, 2021, and cash and cash equivalents of £51.7 million as of September 30, 2022. The increase is attributed to the £55.4 million that was consolidated as a result of the merger with Second Sight.

We believe our cash and cash equivalents as of December 31, 2022, are sufficient to fund operations into the second half of 2024.Research and Development Expense: Research and development expenses increased from £11.0 million in 2021 to £14.2 million in 2022, an increase of £3.2 million, or 29%. The increase from the prior year was primarily due to increased use of outside contractors associated with product design, development and manufacturing associated with our products, increased headcount and professional fees, along with inclusion of new neuromodulation division costs.General and Administrative Expense: General and administrative expenses increased from £2.3 million in 2021 to £7.1 million in 2022, an increase of £4.8 million, or 205%. The increase is related to a provision for a legal claim of £1.7 million and increased accounting and legal costs and other expenses related to our merger of approximately £1.5 million and the general and administrative costs of the neuromodulation division since the merger of £1.1 million.Operating Expense: Operating expenses were £21.2 million for the year ended December 31, 2022, compared to £13.3 million for the year ended December 31, 2021, representing an increase of £7.9 million, or 59%.Net Loss: The net loss was £13.9 million in 2022, as compared to £12.8 million in 2021.

The £1.1 million increase in net loss from 2021 to 2022 was primarily attributable to a £7.9 million increase in operating expenses offset by a £6.9 million gain on the bargain purchase and increased interest income due to rate increases on cash investments.About Vivani Medical, Inc.Leveraging its proprietary NanoPortal platform, Vivani Medical develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time, with the goal of guaranteeing patient adherence to their medication. Vivani’s lead program, which is under development within our Biopharm Division, is NPM-119, a miniaturized, 6-month GLP-1 implant under investigation for the treatment of patients with type 2 diabetes. NPM-119 is designed to provide patients with the opportunity to realize the full potential benefit of their medication while avoiding the challenges associated with the daily or weekly administration of oral and injectable products.

Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarmingly substantial number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than £500 billion in avoidable healthcare costs and 125,000 potentially preventable deaths per year in the US alone, is a primary reason why type 2 diabetes treatments face significant challenges in achieving positive real-world effectiveness.

Vivani’s Neuromodulation Division, recently incorporated as the wholly-owned subsidiary Cortigent, Inc., has developed, manufactured, and marketed implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. Cortigent continues to assess strategic options for advancing Orion II, a visual prosthetic device designed to treat profound blindness and other applications of its pioneering neurostimulation technology.Forward-Looking StatementsThis press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding our business, product candidates, including the therapeutic potential thereof and the planned development therefor, technology and strategy.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.

Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of our product candidates, including NPM-119; delays and changes in applicable laws, regulations and guidelines including potential delays in submitting required regulatory applications to the U.S.

Food and Drug Administration (“FDA”); risks related to the initiation, enrollment and conduct of our planned clinical trials and the results therefrom; our history of losses and our ability to achieve or sustain profitability in the future; and the impact of COVID-19 on our business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”), and the Company’s final proxy statement/prospectus filed with the Commission on June 24, 2022.

Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made.

The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. 

Tags:

gardening-direct listed on couponmatrix.ukhandles4doors listed on couponmatrix.ukinsure-4-a-day listed on couponmatrix.ukpaultons-park listed on couponmatrix.ukprotect-your-bubble listed on couponmatrix.uktupperware listed on couponmatrix.uk
gardening-direct listed on couponmatrix.ukGardening Direct offers top quality plants at affordable prices, grown under greenhouse conditions and delivered straight to your door. If you’d like to brighten up your garden beds or boost your veg patch, you’ve come to the right place—a Gardening Direct discount code from us will help you save even more on your next garden haul! Whether you’re a gardening novice or have a veritable green thumb, you’ll find the plants, bulbs and seeds you’re after at Gardening Direct.
handles4doors listed on couponmatrix.ukOpen up to a world of savings with one of Groupon's Handles4Doors discount codes. You'll gain discounted access to a top supplier of architectural ironmongery which stocks door handles, locks, hinges and knobs to both trade and domestic customers. Their online shop is home to thousands of door fixtures and fittings in a wealth of styles, finishes and designs from top brands - all with a focus on quality, style and performance. Browse the selection and pick up an item for less with one of our Handles4Doors promo codes. The family-run Handles4doors started off life in a small, rustic warehouse in the Farnham countryside, but their success in recent years has taken them to a larger professional warehouse in Fleet. Their team pride themselves on product knowledge and quality service and are always happy to help. With over 50 years industry experience between them, their sales and technical team can give reliable, up-to-date advice and recommendations, or customers can visit the Handles4 Doors showroom for hands-on advice. Handles4Doors caters for both small home improvement projects and commercial projects on a large scale, and through their huge network of suppliers and contacts are able to source specific products and information that might not be available on the site. Since the launch of their first online shop in July 2007 Handles4Doors has gone from strength to strength, and they currently work with some of the leading manufacturers in the ironmongery and homeware industry including Urfic Door Handles, Hafele, Hettich, Pro Décor, Carlisle Brass, Kirkpatrick and Fortessa. So no matter whether you're after contemporary, traditional, rustic or classic style handles, check out Groupon's Handles4Doors voucher codes and kit yourself out in no time.
insure-4-a-day listed on couponmatrix.ukIf you're on the hunt for great-value temporary and short term car hire, you'll love Insure 4 a Day. Providing up to 28 days of instant comprehensive cover, you can start your short break or road trip adventure right away. What's more, when you apply a Insure 4 a Day promo code to your purchase, you can stay safely covered for even less. Insure 4 a Day is the ideal solution for covering additional drivers and for topping up cover for learner drivers too!
paultons-park listed on couponmatrix.ukFun and family frolics are part of the package when it comes to Paultons Park. With the perfect combination of rides, attractions, gardens and activities, families can make plenty of memories on a limited budget by booking with the latest Paultons Park discount code from Groupon. Home to dozens of exotic birds, special seasonal events and even Peppa Pig, boredom is the only item that’s not on the agenda at Paultons Park.
protect-your-bubble listed on couponmatrix.ukGlued at the fingertips to your trusty gadgets and smartphone? Give your gear the protection it deserves with the great insurance deals from ProtectYourBubble.com. Use your Protect Your Bubble promo code to cut the cost of covering your precious mobile, laptop, tablet and more. With easy-to-understand policies and backed by a Fortune 500 company, you can rest assured your possessions are in the safest of hands.
tupperware listed on couponmatrix.ukTupperware is so great at what it does that it’s basically synonymous with “food container”. Whether you’re storing leftovers, preparing salads and overnight oats, microwaving pasta or prolonging the life of your veggies, some plastic or glass Tupperware containers are kitchen essentials. While you can find them almost anywhere, we recommend buying from the brand directly for a bigger selection and the chance to use a Tupperware discount code. The humble plastic boxes are still perfect for most jobs, but you can make your food go further with innovative items like the Tupperware FridgeSmart sets and boost your bread life with the BreadSmart range.